Wells Fargo & Company MN maintained its stake in shares of Accuray Incorporated (NASDAQ:ARAY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,123 shares of the medical equipment provider’s stock at the end of the first quarter. Wells Fargo & Company MN’s holdings in Accuray were worth $290,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the company. Acadian Asset Management LLC boosted its stake in shares of Accuray by 14.2% in the first quarter. Acadian Asset Management LLC now owns 47,765 shares of the medical equipment provider’s stock worth $227,000 after buying an additional 5,926 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Accuray during the first quarter worth approximately $141,000. Teachers Advisors LLC boosted its stake in shares of Accuray by 1.1% in the fourth quarter. Teachers Advisors LLC now owns 123,098 shares of the medical equipment provider’s stock worth $566,000 after buying an additional 1,314 shares during the period. Norges Bank bought a new stake in shares of Accuray during the fourth quarter worth approximately $9,179,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Accuray by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 672,494 shares of the medical equipment provider’s stock worth $3,093,000 after buying an additional 25,075 shares during the period. 84.22% of the stock is owned by institutional investors and hedge funds.

Accuray Incorporated (NASDAQ ARAY) opened at 4.60 on Wednesday. The company’s market capitalization is $381.80 million. Accuray Incorporated has a 12-month low of $3.85 and a 12-month high of $6.39. The firm’s 50-day moving average price is $4.44 and its 200 day moving average price is $4.78.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.01 by $0.07. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $110.23 million. Accuray had a negative return on equity of 61.49% and a negative net margin of 8.61%. Accuray’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period last year, the company earned $0.01 EPS. On average, analysts expect that Accuray Incorporated will post ($0.30) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/07/19/wells-fargo-company-mn-has-290000-position-in-accuray-incorporated-nasdaqaray.html.

A number of brokerages recently commented on ARAY. Zacks Investment Research raised Accuray from a “strong sell” rating to a “hold” rating in a research note on Monday. Aegis reiterated a “buy” rating on shares of Accuray in a report on Tuesday, March 21st. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 target price on shares of Accuray in a report on Friday, June 30th. Finally, BTIG Research reiterated a “hold” rating on shares of Accuray in a report on Sunday, April 30th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $7.04.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.